China Expects M&A, Sharper Competition To Result From New Drug Policy
This article was originally published in PharmAsia News
Executive Summary
China's Health Ministry is looking to its new essential drugs policy to spur drug maker competition, along with the potential for mergers and acquisitions. The head of the ministry's program called the policy the central part of the nation's medical reform plan. He said establishing a competitive bidding process for drug makers to sell to the government means all makers of the same drug are not going to succeed. That means more mergers and acquisitions are likely to result in China, he said. Domestic generics makers are expected to be the major beneficiaries of the new policy. (Click here for more
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.